CO5660275A2 - Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 - Google Patents
Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5Info
- Publication number
- CO5660275A2 CO5660275A2 CO05126935A CO05126935A CO5660275A2 CO 5660275 A2 CO5660275 A2 CO 5660275A2 CO 05126935 A CO05126935 A CO 05126935A CO 05126935 A CO05126935 A CO 05126935A CO 5660275 A2 CO5660275 A2 CO 5660275A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitor
- pde5
- pde4
- phosphodiesterase
- disease
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title abstract 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title abstract 3
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 3
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 6
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 6
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 6
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 6
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03011609 | 2003-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5660275A2 true CO5660275A2 (es) | 2006-07-31 |
Family
ID=33462087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05126935A CO5660275A2 (es) | 2003-05-22 | 2005-12-16 | Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20060094723A1 (https=) |
| EP (1) | EP1628682B1 (https=) |
| JP (1) | JP2006528229A (https=) |
| KR (1) | KR20060012004A (https=) |
| CN (1) | CN1791429A (https=) |
| AU (1) | AU2004241749B2 (https=) |
| BR (1) | BRPI0410326A (https=) |
| CA (1) | CA2525946C (https=) |
| CO (1) | CO5660275A2 (https=) |
| EA (1) | EA012279B1 (https=) |
| EC (1) | ECSP056173A (https=) |
| GE (1) | GEP20084342B (https=) |
| IL (1) | IL171306A (https=) |
| IS (1) | IS8181A (https=) |
| MA (1) | MA27855A1 (https=) |
| MX (1) | MXPA05012302A (https=) |
| NO (1) | NO333501B1 (https=) |
| NZ (1) | NZ544040A (https=) |
| RS (1) | RS52730B (https=) |
| TN (1) | TNSN05265A1 (https=) |
| UA (1) | UA83041C2 (https=) |
| WO (1) | WO2004103407A2 (https=) |
| ZA (1) | ZA200508116B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| PT1606261E (pt) | 2003-03-10 | 2010-01-11 | Nycomed Gmbh | Novo processo para a preparação de roflumilast |
| WO2005023253A1 (en) | 2003-09-05 | 2005-03-17 | Altana Pharma Ag | Use of pde4 inhibitors for the treatment of diabetes mellitus |
| EP1755595A1 (en) * | 2004-05-10 | 2007-02-28 | Altana Pharma AG | Use of roflumilast for the prophylaxis or treatment of emphysema |
| WO2006094942A1 (en) * | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
| AU2006222060B2 (en) * | 2005-03-08 | 2011-09-01 | Takeda Gmbh | Roflumilast for the treatment of diabetes mellitus |
| US8663694B2 (en) | 2005-03-16 | 2014-03-04 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
| DE102005016345A1 (de) * | 2005-04-09 | 2006-10-12 | Bayer Healthcare Ag | Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
| NZ561746A (en) * | 2005-04-19 | 2011-09-30 | Nycomed Gmbh | Roflumilast for the treatment of pulmonary hypertension |
| NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
| EP2359826B1 (en) | 2006-07-05 | 2013-10-30 | Takeda GmbH | Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases |
| WO2008041118A2 (en) * | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| WO2010013925A2 (en) * | 2008-07-31 | 2010-02-04 | Dong-A Pharmaceutical. Co., Ltd. | Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof |
| CN103826638B (zh) * | 2011-09-09 | 2015-11-25 | Sk化学公司 | 含有pde5 抑制剂的减少皮肤皱纹的组合物 |
| CN107007597A (zh) | 2012-05-31 | 2017-08-04 | 菲尼克斯药品股份公司 | 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途 |
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| EP3165224A1 (en) | 2015-11-09 | 2017-05-10 | Albert-Ludwigs-Universität Freiburg | Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders |
| US10058545B2 (en) * | 2016-08-09 | 2018-08-28 | Cipla Limited | Method of treating pulmonary arterial hypertension |
| CN107648224A (zh) * | 2017-10-31 | 2018-02-02 | 泰州中国医药城中医药研究院 | 一种治疗和预防心力衰竭药物及其在制药中的应用 |
| US12582809B2 (en) | 2018-01-26 | 2026-03-24 | Bt Bidco, Inc. | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor |
| CN108976107B (zh) * | 2018-08-23 | 2021-03-23 | 南方医科大学 | 3-芳基-4-烷氧基苄胺衍生物及其制备方法和应用 |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US20230124467A1 (en) * | 2020-03-03 | 2023-04-20 | Mios Pharmaceuticals Limited | Compounds and methods for treating diseases and/or conditions caused by coronavirus |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| ES2176252T3 (es) | 1993-07-02 | 2002-12-01 | Altana Pharma Ag | Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos. |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| KR970705562A (ko) * | 1994-08-29 | 1997-10-09 | 오노다 마사요시 | 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof) |
| US6127363A (en) * | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US6362178B1 (en) | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| US6417190B1 (en) * | 1998-12-17 | 2002-07-09 | Boehringer Ingelheim Pharma Kg | Tricyclic nitrogen heterocycles as PDE IV inhibitors |
| TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| EE05386B1 (et) * | 2001-02-15 | 2011-02-15 | ALTANA�Pharma�AG | Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim |
| WO2002096423A2 (en) * | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
| US20030216407A1 (en) * | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| GB0202254D0 (en) * | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
-
2004
- 2004-05-19 EA EA200501690A patent/EA012279B1/ru not_active IP Right Cessation
- 2004-05-19 CN CNA2004800133493A patent/CN1791429A/zh active Pending
- 2004-05-19 GE GEAP20049115A patent/GEP20084342B/en unknown
- 2004-05-19 CA CA2525946A patent/CA2525946C/en not_active Expired - Fee Related
- 2004-05-19 US US10/556,888 patent/US20060094723A1/en not_active Abandoned
- 2004-05-19 UA UAA200511710A patent/UA83041C2/ru unknown
- 2004-05-19 RS YU20050858A patent/RS52730B/sr unknown
- 2004-05-19 EP EP04766017.0A patent/EP1628682B1/en not_active Expired - Lifetime
- 2004-05-19 JP JP2006530210A patent/JP2006528229A/ja active Pending
- 2004-05-19 NZ NZ544040A patent/NZ544040A/en not_active IP Right Cessation
- 2004-05-19 MX MXPA05012302A patent/MXPA05012302A/es active IP Right Grant
- 2004-05-19 KR KR1020057021796A patent/KR20060012004A/ko not_active Ceased
- 2004-05-19 AU AU2004241749A patent/AU2004241749B2/en not_active Ceased
- 2004-05-19 WO PCT/EP2004/050869 patent/WO2004103407A2/en not_active Ceased
- 2004-05-19 BR BRPI0410326-2A patent/BRPI0410326A/pt active Search and Examination
-
2005
- 2005-10-07 ZA ZA200508116A patent/ZA200508116B/en unknown
- 2005-10-09 IL IL171306A patent/IL171306A/en not_active IP Right Cessation
- 2005-10-18 TN TNP2005000265A patent/TNSN05265A1/en unknown
- 2005-11-17 EC EC2005006173A patent/ECSP056173A/es unknown
- 2005-12-12 MA MA28653A patent/MA27855A1/fr unknown
- 2005-12-14 NO NO20055941A patent/NO333501B1/no not_active IP Right Cessation
- 2005-12-14 IS IS8181A patent/IS8181A/is unknown
- 2005-12-16 CO CO05126935A patent/CO5660275A2/es active IP Right Grant
-
2010
- 2010-05-24 US US12/785,973 patent/US20100234382A1/en not_active Abandoned
-
2012
- 2012-04-12 US US13/445,675 patent/US20120196867A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA012279B1 (ru) | 2009-08-28 |
| MA27855A1 (fr) | 2006-04-03 |
| MXPA05012302A (es) | 2006-01-30 |
| NO333501B1 (no) | 2013-06-24 |
| RS52730B (sr) | 2013-08-30 |
| US20120196867A1 (en) | 2012-08-02 |
| ZA200508116B (en) | 2007-01-31 |
| BRPI0410326A (pt) | 2006-05-23 |
| EA200501690A1 (ru) | 2006-06-30 |
| JP2006528229A (ja) | 2006-12-14 |
| AU2004241749A1 (en) | 2004-12-02 |
| CA2525946A1 (en) | 2004-12-02 |
| NO20055941L (no) | 2005-12-14 |
| TNSN05265A1 (en) | 2007-07-10 |
| EP1628682B1 (en) | 2013-09-25 |
| RS20050858A (sr) | 2007-12-31 |
| AU2004241749B2 (en) | 2010-03-25 |
| CN1791429A (zh) | 2006-06-21 |
| WO2004103407A3 (en) | 2005-02-17 |
| US20060094723A1 (en) | 2006-05-04 |
| KR20060012004A (ko) | 2006-02-06 |
| IS8181A (is) | 2005-12-14 |
| GEP20084342B (en) | 2008-03-25 |
| UA83041C2 (ru) | 2008-06-10 |
| CA2525946C (en) | 2013-01-29 |
| US20100234382A1 (en) | 2010-09-16 |
| ECSP056173A (es) | 2006-04-19 |
| IL171306A (en) | 2013-08-29 |
| NZ544040A (en) | 2009-03-31 |
| WO2004103407A2 (en) | 2004-12-02 |
| EP1628682A2 (en) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5660275A2 (es) | Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
| AR077573A2 (es) | Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende | |
| AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| FR2869231B1 (fr) | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine | |
| CR10838A (es) | Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis | |
| PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
| UY28931A1 (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
| ECSP055783A (es) | Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevención de diabetes | |
| AR054139A1 (es) | Formulacion modificada y de liberacion inmediata de esferas de memantina | |
| CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
| IL192103A0 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression | |
| AR028959A1 (es) | Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares | |
| NZ577393A (en) | Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction | |
| AR051968A1 (es) | Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central | |
| AR043660A1 (es) | El tratamiento de la enfermedad de alzheimer | |
| AR044452A1 (es) | Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa | |
| BR0317095A (pt) | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease | |
| CO6470875A2 (es) | Un compuesto para usar en la prevención y tratamiento de enfermedades cardiovasculares | |
| AR052830A1 (es) | Regimen de cladribina para tratar esclerosis multiple | |
| BRPI0408500A (pt) | tratamento do diabetes do tipo 1 com inibidores de pde5 | |
| BRPI0508333A (pt) | uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit | |
| UY28182A1 (es) | Uso de dipiridamol en combinación con ácido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular | |
| CR9444A (es) | Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |